|
| Status |
Public on Jun 16, 2021 |
| Title |
Infinium MethylationEPIC BeadChip array data for HGSOC PH039 PDXs at baseline and treated with cycles of 100 mg/kg niraparib for 21 days for four treatment rounds and murine sample. |
| Platform organism |
Homo sapiens |
| Sample organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Methylation profiling by genome tiling array
|
| Summary |
Infinium MethylationEPIC BeadChip array data for HGSOC PH039 PDXs at baseline and treated with cycles of 100 mg/kg niraparib for 21 days for four treatment rounds and murine sample.
|
| |
|
| Overall design |
Infinium MethylationEPIC BeadChip data of 8 samples: Niraparib arm (n=4 over three treatment cycles) or source tumor arm passaged without drug (n=4) passaged ).
HGSOC= high grade serous ovarian cancer
PDX= personalized derived xenograph
|
| |
|
| Contributor(s) |
Kaufmann S, Li H, Ming Wong E, Southey MC, Ksenija N, Kondrashova O, Wakefield M, Scott C |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jan 18, 2021 |
| Last update date |
Jun 19, 2021 |
| Contact name |
Hu Li |
| E-mail(s) |
li.hu@mayo.edu
|
| Organization name |
Mayo Clinic
|
| Department |
Molecular Pharmacology & Experimental Therapeutics
|
| Lab |
Systems Biology and Pharmacology
|
| Street address |
200 First Street, Gonda Building G19-408
|
| City |
Rochester |
| State/province |
MN |
| ZIP/Postal code |
55904 |
| Country |
USA |
| |
|
| Platforms (1) |
|
| Samples (10)
|
| GSM5025301 |
S0.1: Sensitive PH039 source tumor (array) |
| GSM5025302 |
S0.2: Sensitive PH039 source tumor (array) |
| GSM5025303 |
S2.1: Sensitive PH039 second passage source tumor (array) |
| GSM5025304 |
S2.3-rep1: Sensitive PH039 second passage source tumor (array) |
| GSM5025305 |
C1.2: Sensitive PH039 first passage niraparib treated tumor (array) |
| GSM5025306 |
C2.1: PH039 second passage niraparib treated tumor (array) |
| GSM5025307 |
C2.2: PH039 second passage niraparib treated tumor (array) |
| GSM5025308 |
C3.1: Resistant PH039 third passage niraparib treated tumor (array) |
| GSM5025309 |
148B: Murine sample (array) |
| GSM5025310 |
S2.3-rep2: Sensitive PH039 second passage source tumor (array) |
|
| This SubSeries is part of SuperSeries: |
| GSE165052 |
Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development |
|
| Relations |
| BioProject |
PRJNA693040 |
Less...
More...